Robinson D S, Nies A
Mod Probl Pharmacopsychiatry. 1975;10:57-64. doi: 10.1159/000397919.
Evidence for the genetic control of human MAO is now well established. The relationships of MAO activities to neuropsychiatric disorders or response to psychopharmacologic treatments are relatively unstudied. Preliminary findings from our own studies suggest that (1) blood MAO activity is a polygenically controlled trait; (2) there may be a subgroup of depressed patients with high MAO activity who are more severe symptomatically and more resistant to treatment, and (3) that men with atypical and mixed depressions respond more favorably than women to treatment with an MAO inhibitory drug.
人类单胺氧化酶（MAO）受基因控制的证据现已确凿。MAO活性与神经精神疾病或对精神药物治疗反应之间的关系相对较少研究。我们自己研究的初步结果表明：（1）血液MAO活性是一种受多基因控制的性状；（2）可能存在一个MAO活性高的抑郁症患者亚组，他们症状更严重且对治疗更具抗性；（3）非典型和混合性抑郁症男性患者比女性患者对MAO抑制药物治疗反应更佳。
